

## TABLE OF CATHINONES AND CATHINONE DERIVATIVES BILLS, STATUTES & REGULATIONS

© 2011 Research is current as of July 22, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

The following table illustrates what the states are doing with regard to scheduling cathinones and cathinone derivatives and, where indicated, which states have already scheduled the substances by statute (S) or regulation (R).

|                          | <u>cathinone<sup>1</sup></u> | methcathinone <sup>2</sup> | mephedrone <sup>3</sup> | methedrone <sup>4</sup> | Flephedrone <sup>5</sup> | <u>3-FMC<sup>6</sup></u> | methylone <sup>7</sup> | MDPV <sup>8</sup> |
|--------------------------|------------------------------|----------------------------|-------------------------|-------------------------|--------------------------|--------------------------|------------------------|-------------------|
| Alabama                  | X(R)                         | X(R)                       | X                       | X                       | X                        | Х                        | X                      | Х                 |
| Alaska                   |                              | X(S)                       |                         |                         |                          |                          |                        |                   |
| Arizona <sup>9</sup>     | X(S)                         | X(S)                       | X                       |                         |                          |                          | X                      | х                 |
| Arkansas <sup>10</sup>   | X(R)                         | X(R)                       | X                       | Х                       | X                        | X                        | х                      | X                 |
| California <sup>11</sup> | X(S)                         |                            |                         |                         |                          |                          |                        |                   |
| Colorado                 | X(S)                         | X(S)                       |                         |                         |                          |                          |                        |                   |

<sup>&</sup>lt;sup>1</sup> 2-amino-1-phenyl propanone

<sup>&</sup>lt;sup>2</sup> 2-methylamino-1-phenylpropan-1-one

<sup>&</sup>lt;sup>3</sup> 4-methylmethcathinone; 4-MMC; 4-methylephedrone; (RS)-2-methylamino-1-(4-methylphenyl)propan-1-one

<sup>&</sup>lt;sup>4</sup> Bk-PMMA; para-methoxymethcathinone; 4-methoxymethcathinone; PMMC; methoxyphedrine; (RS)-1-(4-methoxyphenyl)-2-(methylamino)propan-1-one

<sup>&</sup>lt;sup>5</sup> 4-fluoromethcathinone

<sup>&</sup>lt;sup>6</sup> 3-fluoromethcathinone

<sup>&</sup>lt;sup>7</sup> 3,4-methylenedioxy-N-methylcathinone; bk-MDMA; MDMC

<sup>&</sup>lt;sup>8</sup> Methylenedioxypyrovalerone; MDPK; 3,4-methylenedioxypyrovalerone

<sup>&</sup>lt;sup>9</sup> Arizona proposes to schedule methylmethcathinone and methylenedioxymethylcathinone generally.

<sup>&</sup>lt;sup>10</sup> Arkansas also proposes to add the ACMD generic language.

<sup>&</sup>lt;sup>11</sup> California has proposed to add the ACMD generic language.

<sup>© 2011</sup> Research is current as of July 22, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

| Connecticut            | X(R)  | X(R)  | x               |   |                 |                 |      | X    |
|------------------------|-------|-------|-----------------|---|-----------------|-----------------|------|------|
| Connecticut            | X(II) | Λ(ιι) |                 |   |                 |                 |      |      |
| Delaware               | X(S)  | X(S)  |                 |   |                 |                 |      |      |
| District of            |       |       |                 |   |                 |                 |      |      |
| Columbia               | X(S)  |       |                 |   |                 |                 |      |      |
|                        |       |       |                 |   |                 |                 |      |      |
| Florida <sup>12</sup>  | X(S)  | X(S)  | X(R)            | X | X(R)            | X(R)            | X(R) | X(R) |
|                        |       |       |                 |   |                 |                 |      |      |
| Georgia                | X(S)  | X(S)  | X               | Χ | X               |                 | X    | Х    |
|                        |       | , ,   |                 |   |                 |                 |      |      |
| Hawaii                 | X(S)  | X(S)  | X               |   |                 |                 |      | Х    |
|                        |       | , ,   |                 |   |                 |                 |      |      |
| Idaho <sup>13</sup>    | X(S)  | X(S)  |                 |   |                 |                 |      |      |
| 10.01.10               | 7.(0) | 7.(0) |                 |   |                 |                 |      |      |
| Illinois <sup>14</sup> | X(S)  | X(S)  | x               | X | X               | Х               | x    | x    |
|                        | 7.(0) | 7.(0) | 7.              |   |                 |                 |      |      |
| Indiana                | X(S)  | X(S)  | x               | Χ | X <sup>15</sup> | X <sup>15</sup> | X    | X    |
| IIIuiaiia              | 7(3)  | Λ(3)  | ^               | ^ | ^               | ^               | ^    | ^    |
| lowa                   | X(S)  | X(S)  | X <sup>16</sup> |   |                 |                 |      | X    |

\_

<sup>&</sup>lt;sup>12</sup> Florida scheduled mephedrone, 4-fluoromethcathinone, 3-fluoromethcathinone, methylone and MDPV by rule on an emergency basis on January 26, 2011. 2ER11-1. Florida is also proposing to schedule all substances.

<sup>&</sup>lt;sup>13</sup> Idaho is proposing to add the ACMD generic language.

<sup>&</sup>lt;sup>14</sup> Illinois is proposing to add the ACMD generic language.

<sup>&</sup>lt;sup>15</sup> Indiana is proposing to schedule "fluoromethcathinone" generally.

<sup>&</sup>lt;sup>16</sup> lowa is proposing to schedule (RS)-2-methylamino-1-(4-methylphenyl)propan-1-one, a/k/a 4-MMC, as "mephedrine" in one bill.

<sup>© 2011</sup> Research is current as of July 22, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

| Kansas <sup>17</sup>      | X(S) | X(S) |                    |      |      |      |      |      |
|---------------------------|------|------|--------------------|------|------|------|------|------|
| Kentucky                  | X(R) | X(S) | Х                  |      |      |      | Х    | х    |
| Louisiana <sup>18</sup>   | X(S) | X(S) | X(R)               | X(R) | X(R) | X(R) | X(R) | X(R) |
| Maine                     |      |      | Х                  | Х    | Х    | X    | Х    | Х    |
| Maryland                  |      |      |                    |      |      |      |      |      |
| Massachusetts             |      |      |                    |      |      |      |      |      |
| Michigan                  | X(S) | X(S) | X(S) <sup>19</sup> |      |      |      |      | Х    |
| Minnesota                 | X(S) | X(S) | Х                  | X    |      |      | Х    | Х    |
| Mississippi <sup>20</sup> | X(S) | X(S) | Х                  |      |      |      |      | х    |
| Missouri                  | X(S) | X(S) | Х                  | Х    | Х    | x    | Х    | Х    |

-

<sup>&</sup>lt;sup>17</sup> Kansas is proposing to add a version of the ACMD generic language.

Louisiana scheduled mephedrone, methedrone, 4-fluoromethcathinone, 3-fluoromethcathinone, methylone, and MDPV by regulation on an emergency basis on January 20, 2011. 2011 Reg. Text 247982. Louisiana is also proposing to add the ACMD generic language.

<sup>&</sup>lt;sup>19</sup> Michigan schedules 4-methylmethcathinone as "mephradone" under M.C.L.A. §333.7212. Michigan has a bill proposed that would change it from "mephradone" to "mephedrone."

<sup>&</sup>lt;sup>20</sup> Mississippi proposes to add the ACMD generic language.

<sup>© 2011</sup> Research is current as of July 22, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

| Montana                      | X(S) | X(S) |                    |   |   |   |   |                    |
|------------------------------|------|------|--------------------|---|---|---|---|--------------------|
| Nebraska                     | X(S) | X(S) |                    |   |   |   |   |                    |
| Nevada                       | X(R) | X(R) | х                  | х | х | Х | Х | Х                  |
| New Hampshire <sup>21</sup>  | X(R) | X(R) |                    |   |   |   |   |                    |
| New Jersey                   |      |      | х                  | Х | х | Х | Х | X                  |
| New Mexico                   | X(R) | X(R) | Х                  | Х | Х | X | Х | Х                  |
| New York <sup>22</sup>       | X(S) | X(S) | х                  | Х | х | Х | Х | X                  |
| North Carolina <sup>23</sup> | X(S) | X(S) | Х                  |   |   |   |   | X                  |
| North Dakota                 | X(S) | X(S) | X(R) <sup>24</sup> |   |   |   |   | X(R) <sup>24</sup> |
| Ohio                         | X(S) | X(S) | х                  | X | X | X | X | X                  |
| Oklahoma                     |      | X(S) | X                  | Х | Х | X | Х | X                  |

\_

<sup>&</sup>lt;sup>21</sup> New Hampshire references the federal code, 21 USC 801, et seq., for its list of scheduled substances.

<sup>&</sup>lt;sup>22</sup> New York is proposing to add the ACMD generic language.

<sup>&</sup>lt;sup>23</sup> North Carolina is proposing to add the ACMD generic language.

North Dakota also has a proposed bill, 2011 ND S.B. 2119, that would schedule mephedrone and MDPV by statute.

<sup>© 2011</sup> Research is current as of July 22, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

| Oregon <sup>25</sup>    | X(R) | X(R)     | X(R) | X(R)            | X(R)            | X(R)            | X(R) | X(R) |
|-------------------------|------|----------|------|-----------------|-----------------|-----------------|------|------|
| 0.080                   | 7.(, | 7.(,     | 7.(, | 7.()            | 7.(,            | 7.(,            | 7.(, | 7.(, |
| Pennsylvania            | X(R) | X(R)     | Х    | Х               | Х               | X               | Х    | х    |
| Rhode Island            |      |          | Х    | X <sup>26</sup> | X <sup>27</sup> | X <sup>27</sup> | Х    | Х    |
| South Carolina          |      |          | Х    | X <sup>28</sup> | X <sup>29</sup> | X <sup>29</sup> | X    | X    |
| South Dakota            | X(S) | X(S)     |      |                 |                 |                 |      |      |
| Tennessee <sup>30</sup> | X(R) | X(R) (S) | X    | X               | X               | X               | X    | X    |
| Texas <sup>31</sup>     | X(S) | X(S)     | X    |                 | х               | X               | х    | X    |
| Utah                    | X(S) | X(S)     | х    | х               | Х               | Х               | Х    | х    |
| Vermont                 |      | X(R)     |      |                 |                 |                 |      |      |

-

<sup>&</sup>lt;sup>25</sup> The Oregon Board of Pharmacy adopted a regulation on May 1, 2011 that schedules methylmethcathinone (mephedrone), MDPV, methylenedioxymethylcathinone (methylone), methedrone, and fluoromethcathinone (flephedrone).

<sup>&</sup>lt;sup>26</sup> Rhode Island is proposing to schedule "methoxymethcathinone" generally.

<sup>&</sup>lt;sup>27</sup> Rhode Island is proposing to schedule "fluoromethcathinone" generally.

<sup>&</sup>lt;sup>28</sup> South Carolina is proposing to schedule "methoxymethcathinone" generally.

<sup>&</sup>lt;sup>29</sup> South Carolina is proposing to schedule "fluoromethcathinone" generally.

Tennessee schedules methcathinone by both statute and regulation. Tenn. Code Ann. §39-17-406 classifies methcathinone and Catha edulis as Schedule I drugs when cathinone is present, and Catha edulis as a Schedule IV drug (TCA §39-17-412) when cathinone is absent but cathine is present. TN ADC 0940-06-01-.01 schedules both cathinone and methcathinone as Schedule I substances.

 $<sup>^{\</sup>rm 31}$  Texas is also proposing to add the generic ACMD language.

<sup>© 2011</sup> Research is current as of July 22, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

| Virginia      | X(S) | X(S) | X |   |   |   |   | × |
|---------------|------|------|---|---|---|---|---|---|
| Washington    | X(S) | X(S) |   |   |   |   |   |   |
| West Virginia | X(S) | X(S) | x |   |   |   |   | Х |
| Wisconsin     | X(S) | X(S) | Х |   |   |   |   | Х |
| Wyoming       | X(S) | X(S) | Х | X | Х | X | X | X |

<sup>(</sup>S) = Substance is scheduled by statute

© 2011 Research is current as of July 22, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

<sup>(</sup>R) = Substance is scheduled or proposed to be scheduled by regulation